Allianz Asset Management Ag Has Decreased Korea Electric Pwr (KEP) Holding; 5 Analysts Bullish pSivida Corp. (PSDV)

September 17, 2017 - By Marguerite Chambers

Allianz Asset Management Ag decreased Korea Electric Pwr (KEP) stake by 10.06% reported in 2016Q4 SEC filing. Allianz Asset Management Ag sold 486,256 shares as Korea Electric Pwr (KEP)’s stock rose 7.41%. The Allianz Asset Management Ag holds 4.35 million shares with $80.33M value, down from 4.83M last quarter. Korea Electric Pwr now has $23.36B valuation. The stock increased 2.24% or $0.4 on September 15, reaching $18.24. About 687,638 shares traded or 141.98% up from the average. Korea Electric Power Corporation (ADR) (NYSE:KEP) has declined 25.10% since September 17, 2016 and is downtrending. It has underperformed by 41.80% the S&P500.

Among 5 analysts covering pSivida (NASDAQ:PSDV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. pSivida had 10 analyst reports since October 15, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 11 by H.C. Wainwright. The stock of pSivida Corp. (NASDAQ:PSDV) earned “Buy” rating by H.C. Wainwright on Friday, June 23. Ladenburg maintained pSivida Corp. (NASDAQ:PSDV) rating on Tuesday, June 13. Ladenburg has “Buy” rating and $12.5000 target. The stock has “Buy” rating by Northland Capital on Wednesday, June 14. The rating was maintained by H.C. Wainwright on Wednesday, June 14 with “Buy”. The stock of pSivida Corp. (NASDAQ:PSDV) earned “Buy” rating by FBR Capital on Tuesday, June 13. H.C. Wainwright maintained the shares of PSDV in report on Tuesday, May 30 with “Buy” rating. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) on Tuesday, September 12 with “Buy” rating. FBR Capital initiated the stock with “Outperform” rating in Thursday, October 15 report. See pSivida Corp. (NASDAQ:PSDV) latest ratings:

12/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
11/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain
23/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0000 Maintain
13/06/2017 Broker: FBR Capital Rating: Buy Maintain
14/06/2017 Broker: Northland Capital Rating: Buy New Target: $10.0000 Maintain
14/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0000 Maintain
13/06/2017 Broker: Ladenburg Rating: Buy New Target: $12.5000 Maintain
30/05/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0000 Maintain
30/05/2017 Broker: Rodman \u0026 Renshaw Rating: Buy New Target: $8 Initiates Coverage On

Among 4 analysts covering Korea Electric Power (NYSE:KEP), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Korea Electric Power had 6 analyst reports since August 26, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Monday, November 21 by Bank of America. The firm has “Hold” rating given on Tuesday, February 7 by HSBC. Credit Suisse downgraded the stock to “Neutral” rating in Wednesday, May 10 report. Morgan Stanley downgraded the shares of KEP in report on Tuesday, June 21 to “Equal-Weight” rating. As per Monday, March 7, the company rating was downgraded by Bank of America. The firm earned “Sell” rating on Wednesday, August 26 by Zacks.

Allianz Asset Management Ag increased Seacoast Bkg Corp Fla (NASDAQ:SBCF) stake by 517,544 shares to 783,624 valued at $17.29M in 2016Q4. It also upped Xilinx Inc (NASDAQ:XLNX) stake by 659,121 shares and now owns 690,156 shares. Simon Ppty Group Inc New (NYSE:SPG) was raised too.

The stock decreased 0.82% or $0.01 on September 15, reaching $1.21. About 310,464 shares traded or 1.40% up from the average. pSivida Corp. (NASDAQ:PSDV) has declined 20.28% since September 17, 2016 and is downtrending. It has underperformed by 36.98% the S&P500.

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The company has market cap of $47.64 million. The Firm operates through the biotechnology sector segment. It currently has negative earnings. The Firm has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema , its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com